Effect of cabergoline alginate nanocomposite on the transgenic Drosophila melanogaster model of Parkinson’s disease

References

• Abdipranoto A, Wu S, Stayte S, Vissel B. 2008. The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development. CNS Neurol Disord Drug Targets. 7:187–210.
   PubMed Web of Science ®Google Scholar
• Asanuma M, Miyazaki I, Ogawa N. 2003. Dopamine-or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox Res. 5:165–176.
   PubMed Web of Science ®Google Scholar
• Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE. 2001. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson’s disease. J Neurosci. 21:6853–6861.
   PubMed Web of Science ®Google Scholar
• Bonuccelli U, Del Dotto P, Rascol O. 2009. Role of dopamine receptor agonists in the treatment of early Parkinson’s disease. Parkinsonism Relat Disorder. 15:S44–S53.
   PubMed Web of Science ®Google Scholar
• Chanda A, Mohanta D. 2016. Nanotechnology – a potent pharmacological tool. Int J Res Adv Tech. 4:6–16.
   Google Scholar
• Chen SC, Wu YC, Mi FL, Lin YH, Yu LC, Sung HW. 2004. A novel pH-sensitive hydrogel composed of N,O-carboxymethyl chitosan and alginate cross-linked by genipin for protein drug delivery. J Control Release. 96:285–300.
   PubMed Web of Science ®Google Scholar
• Chevion M, Berenshtein E, Stadtman ER. 2000. Human studies related to protein oxidation: protein carbonyl content as a marker of damage. Free Radic Res. 33:S99–S108.
   PubMed Web of Science ®Google Scholar
• Chiu JC, Low KH, Pike DH, Yildirim E, Edery I. 2010. Assaying locomotor activity to study circadian rhythms and sleep parameters in Drosophila. J Vis Exp. 43:e2157.
   Google Scholar
• Dalle Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A. 2006. Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med. 10:389–406.
   PubMed Web of Science ®Google Scholar
• Dauer W, Przedborski S. 2003. Parkinson’s disease: mechanisms and models. Neuron 39:889–909.
   PubMed Web of Science ®Google Scholar
• Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD. 1989. Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem. 52:381–389.
   PubMed Web of Science ®Google Scholar
• Di Marco A, Appiah-Kubi LS, Chaudhuri KR. 2002. Use of the dopamine agonist cabergoline in the treatment of movement disorders. Expert Opin Pharmacother. 3:1481–1487.
   PubMedGoogle Scholar
• Eguchi K, Kawamoto K, Uozumi T, Ito A, Arita K, Kurisu K. 1995. Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies. Endocr J. 42:413–420.
   PubMed Web of Science ®Google Scholar
• Fatima A, Khanam S, Rahul JS, Naz F, Ali F. 2017. Protective effect of tangeritin in transgenic Drosophila model of Parkinson’s disease. Front Biosci. 9:44–53.
   Google Scholar
• Feany MB, Bender WW. 2000. A Drosophila model of Parkinson’s disease. Nature 404:394–398.
   PubMed Web of Science ®Google Scholar
• Finotti N, Castagna L, Moretti A, Marzatico F. 2000. Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment. Pharmacol Res. 42:287–291.
   PubMed Web of Science ®Google Scholar
• Habig WH, Pabst MJ, Fleischner G, Gatmaitan Z, Arias IM, Jakoby WB. 1974. The identity of glutathione S-transferase B with ligandin, a major binding protein of liver. Proc Natl Acad Sci USA. 71:3879–3882.
   PubMed Web of Science ®Google Scholar
• Hawkins CL, Morgan PE, Davies MJ. 2009. Quantification of protein modification by oxidants. Free Radic Biol Med. 46:965–988.
   PubMed Web of Science ®Google Scholar
• Hwang O. 2013. Role of oxidative stress in Parkinson’s disease. Exp Neurobiol. 22:11–17.
   PubMedGoogle Scholar
• Hearn MG, Ren Y, McBride EW, Reveillaud I, Beinborn M, Kopin AS. 2002. A Drosophila dopamine 2-like receptor: molecular characterization and identification of multiple alternatively spliced variants. Proc Natl Acad Sci USA. 99:14554–14559.
   PubMed Web of Science ®Google Scholar
• Jahromi SR, Haddadi M, Shivanandappa T, Ramesh SR. 2015. Attenuation of neuromotor deficits by natural antioxidants of Decalepis hamiltonii in transgenic Drosophila model of Parkinson’s disease. Neuroscience 293:136–150.
   PubMed Web of Science ®Google Scholar
• Jollow DJ, Mitchell JR, Zampaglione NA, Gillette JR. 1974. Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 11:151–169.
   PubMed Web of Science ®Google Scholar
• Junghanns S, Fuhrmann JT, Simonis G, Oelwein C, Koch R, Strasser RH, Reichmann H, Storch A. 2007. Valvular heart disease in Parkinson’s disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord. 22:34–38.
   Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV. 2004. New technologies for drug delivery across the blood brain barrier. Curr Pharm Des. 10:1355–1363.
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Gendelman HE. 2007. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci. 32:1054–1082.
   PubMed Web of Science ®Google Scholar
• Le WD, Jankovic J. 2001. Are dopamine receptor agonists neuroprotective in Parkinson’s disease? Drugs Aging. 18:389–396.
   PubMed Web of Science ®Google Scholar
• Li P, Dai YN, Zhang JP, Wang AQ, Wei Q. 2008. Chitosan-alginate nanoparticles as a novel drug delivery system for nifedipine. Int J Biomed Sci. 4:221–228.
   PubMedGoogle Scholar
• Li T, Shi XW, Du YM, Tang YF. 2007. Quaternized chitosan/alginate nanoparticles for protein delivery. J Biomed Mater Res A. 83:383–390.
   PubMed Web of Science ®Google Scholar
• Long J, Gao H, Sun L, Liu J, Zhao-Wilson X. 2009. Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson’s disease model. Rejuvenation Res. 12:321–331.
   PubMed Web of Science ®Google Scholar
• Meinel J, Radad K, Rausch WD, Reichmann H, Gille G. 2015. Cabergoline protects dopaminergic neurons against rotenoneinduced cell death in primary mesencephalic cell culture. Folia Neuropathol. 1:29–40.
   Google Scholar
• Miglio G, Varsaldi F, Francioli E, Battaglia A, Canonico PL, Lombardi G. 2004. Cabergoline protects SH-SY5Y neuronal cells in an in vitro model of ischemia. Eur J Pharmacol. l489:157–165.
   PubMed Web of Science ®Google Scholar
• Mitchell KJ, Staveley BE. 2006. Protocol for the detection and analysis of cell death in the adult Drosophila brain. Drosoph Inf Serv. 89:118–121.
   Google Scholar
• Morozova N, Khrapko K, Panee J, Liu W, Harney JW, Berry MJ. 2007. Glutathione depletion in hippocampal cells increases levels of H and L ferritin and glutathione S-transferase mRNAs. Genes Cells. 12:561–567.
   PubMed Web of Science ®Google Scholar
• Muñoz-Soriano V, Paricio N. 2011. Drosophila models of Parkinson’s disease: discovering relevant pathways and novel therapeutic strategies. Parkinsons Dis. 2011:1–14.
   Google Scholar
• Nune SK, Gunda P, Thallapally PK, Lin YY, Laird Forrest M, Berkland CJ. 2009. Nanoparticles for biomedical imaging. Expert Opin Drug Deliv. 6:1175–1194.
   PubMed Web of Science ®Google Scholar
• Odaka H, Numakawa T, Adachi N, Ooshima Y, Nakajima S, Katanuma Y, Inoue T, Kunugi H. 2014. Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity. PloS One. 9:e99271.
   PubMed Web of Science ®Google Scholar
• Ohkawa H, Ohishi N, Yagi K. 1978. Reaction of linoleic acid hydroperoxide with thiobarbituric acid. J Lipid Res. 19:1053–1057.
   PubMed Web of Science ®Google Scholar
• Ohta K, Fujinami A, Kuno S, Sakakimoto A, Matsui H, Kawahara Y, Ohta M. 2004. Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology 71:162–168.
   PubMed Web of Science ®Google Scholar
• Pandey UB, Nichols CD. 2011. Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol Rev. 63:411–436.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. 2005. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3–14.
   PubMedGoogle Scholar
• Pendleton RG, Parvez F, Sayed M, Hillman R. 2002. Effects of pharmacological agents upon a transgenic model of Parkinson’s disease in Drosophila melanogaster. J Pharmacol Exp Ther. 300:91–96.
   PubMed Web of Science ®Google Scholar
• Polidori MC, Griffiths HR, Mariani E, Mecocci P. 2007. Hallmarks of protein oxidative damage in neurodegenerative diseases: focus on Alzheimer’s disease. Amino Acids 32:553–559.
   PubMed Web of Science ®Google Scholar
• Rasmussen VG, Østergaard K, Dupont E, Poulsen SH. 2011. The risk of valvular regurgitation in patients with Parkinson’s disease treated with dopamine receptor agonists. Mov Disord. 26:801–806.
   PubMed Web of Science ®Google Scholar
• Rosato E, Kyriacou CP. 2006. Analysis of locomotor activity rhythms in Drosophila. Nat Protoc. 1:559–568.
   PubMed Web of Science ®Google Scholar
• Sandhir R, Yadav A, Sunkaria A, Singhal N. 2015. Nano-antioxidants: an emerging strategy for intervention against neurodegenerative conditions. Neurochem Int. 89:209–226.
   PubMed Web of Science ®Google Scholar
• Sankalia MG, Mashru RC, Sankalia JM, Sutariya VB. 2007. Reversed chitosan-alginate polyelectrolyte complex for stability improvement of alpha-amylase: optimization and physicochemical characterization. Eur J Pharm Biopharm. 65:215–232.
   PubMed Web of Science ®Google Scholar
• Schlumpf M, Lichtensteiger W, Langemann H, Waser PG, Hefti FA. 1974. Fluorometric micromethod for the simultaneous determination of serotonin, noradrenaline and dopamine in milligram amounts of brain tissue. Biochem Pharmacol. 23:2437–2446.
   PubMed Web of Science ®Google Scholar
• Schulz JB. 2007. Mechanisms of neurodegeneration in idiopathic Parkinson’s disease. Parkinsonism Relat Disord. 13:S306–S308.
   PubMed Web of Science ®Google Scholar
• Shacter E. 2000. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev. 32:307–326.
   PubMed Web of Science ®Google Scholar
• Shoeb M, Singh BR, Mobin M, Afreen G, Khan W, Naqvi AH. 2015. Kinetic Study on Mutagenic Chemical Degradation through Three Pot Synthesiszed Graphene@ZnO Nanocomposite. PloS One. 10:e0135055
   PubMed Web of Science ®Google Scholar
• Siddique YH, Khan W, Fatima A, Jyoti S, Khanam S, Naz F, Rahul AF, Singh BR, Naqvi AH. 2016. Effect of bromocriptine alginate nanocomposite (BANC) on a transgenic Drosophila model of Parkinson’s disease. Dis Model Mech. 9:63–68.
   PubMed Web of Science ®Google Scholar
• Siddique YH, Khan W, Singh BR, Naqvi AH. 2013. Synthesis of alginate-curcumin nanocomposite and its protective role in transgenic Drosophila model of Parkinson’s disease. ISRN Pharmacol. 2013:1–8.
   Google Scholar
• Siddique YH, Naz F, Jyoti S, Fatima A, Khanam S, Ali F, Faisal M. 2014. Effect of Centella asiatica leaf extract on the dietary supplementation in transgenic drosophila model of Parkinson’s Disease. Parkinsons Dis. 2014:1–11.
   Google Scholar
• Siddique YH, Naz F, Khan W, Jyoti S, Singh BR, Naqvi AH. 2018. Effect of pramipexole alginate nanodispersion (PAND) on the transgenic Drosophila expressing human alpha synuclein in the brain. J Appl Biomed. 16:111–119.
   Web of Science ®Google Scholar
• Silva GA. 2006. Neuroscience nanotechnology: progress, opportunities and challenges. Nat Rev Neurosci. 7:65–74.
   PubMed Web of Science ®Google Scholar
• Trigo-Damas I, del Rey NLG, Blesa J. 2018. Novel models for Parkinson’s disease and their impact on future drug discovery. Expert Opin Drug Discov. 13:229–239.
   PubMed Web of Science ®Google Scholar
• Vilar L, Abucham J, Albuquerque JL, Araujo LA, Azevedo MF, Boguszewski CL, Casulari LA, Cunha MBC, Czepielewski MA, Duarte FHG, et al. 2018. Controversial issues in the management of hyperprolactinemia and prolactinomas – an overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch. Endocri. Metab. 62:236–263.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Ding H, Xu M, Gao J. 2009. Protective effects of asiatic acid on rotenone- or H2O2-induced injury in SH-SY5Y cells. Neurochem Res. 34:746–754.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Yu J. 2018. Modeling Parkinson’s disease in Drosophila: what have we learned for dominant traits? Front Neurol. 9:228.
   PubMed Web of Science ®Google Scholar
• Xu C-L, Wang Q-Z, Sun L-M, Li X-M, Deng J-M, Li L-F, Zhang J, Xu R, Ma S-P. 2012. Asiaticoside: attenuation of neurotoxicity induced by MPTP in a rat model of Parkinsonism via maintaining redox balance and up-regulating the ratio of Bcl-2/Bax. Pharmacol Biochem Behav. 100:413–418.
   PubMed Web of Science ®Google Scholar
• Yoshioka M, Tanaka KI, Miyazaki I, Fujita N, Higashi Y, Asanuma M, Ogawa N. 2002. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci Res. 43:259–267.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Tanaka M, Suzuki Y, Sohmiya M, Okamoto K. 2002. Antioxidant properties of cabergoline: inhibition of brain auto-oxidation and superoxide anion production of microglial cells in rats. Neurosci Lett. 330:1–4.
   PubMed Web of Science ®Google Scholar
• Zhao B. 2009. Natural antioxidants protect neurons in Alzheimer’s disease and Parkinson’s disease. Neurochem Res. 34:630–638.
   PubMed Web of Science ®Google Scholar
• Zhao L, Longo-Guess C, Harris BS, Lee JW, Ackerman SL. 2005. Protein accumulation and neurodegeneration in the woozy mutant mouse is caused by disruption of SIL1, a cochaperone of BiP. Nat Genet. 37:974–979.
   PubMed Web of Science ®Google Scholar